Antisense oligonucleotides rescue an intronic splicing variant in the ABCB11 gene that causes progressive familial intrahepatic cholestasis type 2. Issue 11 (November 2022)

• Record Type: Journal Article
• Authors: Zheng, Yucan; Zhou, Chunlei; Zheng, Bixia; Hu, Guorui; Wang, Chunli; Zhou, Wei; Lu, Yan; Zhang, Zhihua; Lin, Qian; Guo, Hongmei; Jin, Yu; Liu, Zhifeng; Tang, Weibing
• Is Part Of: Digestive and liver disease. Volume 54:Issue 11(2022)
• Page Start: 1541
• Page End: 1547
• Publication Date: 2022-11
• Subjects: ABCB11 -- Aberrant RNA splicing -- Antisense oligonucleotides -- BSEP -- Intronic variants -- Progressive familial intrahepatic cholestasis type 2; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; 616.33005
• DOI: 10.1016/j.dld.2022.04.002
• Languages: English
• ISSNs: 1590-8658

Abstract

Abstract: Background: Progressive familial intrahepatic cholestasis type 2 (PFIC2) is a rare disorder caused by variants in the ABCB11 gene encoding the bile salt export pump (BSEP). We investigated the molecular defect in a PFIC2 infant and rescued the splicing defect with antisense oligonucleotides (ASOs). Methods: Whole-exome sequencing (WES) revealed compound heterozygous variants in the ABCB11 gene in a PFIC2 patient. Liver biopsy was immunostained for BSEP. The splicing effect of the candidate variants was investigated by minigene assay . ASOs were designed to rescue aberrant splicing. Results: A Chinese girl of two nonconsanguineous healthy parents suffered from low glutamyl transpeptidase cholestasis and showed no response to the ursodeoxycholic acid. WES revealed that the patient was compound heterozygous for two novel variants in the ABCB11 gene: c.76+29T>G and c.390–2A>G. Liver immunohistochemistry showed the absence of BSEP. The variant c.76+29T>G was confirmed to retain 42 bp in the mature mRNA. The variant c.390–2A>G was confirmed to cause exon 6 skipping. We designed two ASOs and identified one of them that efficiently induced pseudoexon exclusion. Conclusion: We reported two novel variants of the ABCB11 gene, c.76+29T>G and c.390-2A>G, in a PFIC2 infant, thereby expanding the genotype of PFIC2. Our findings provide evidence for ASOs as a therapeutic approach for PFIC2 patients carrying intronic variants.